title: Monoclonal antibodies in treatment of multiple sclerosis.
abstract: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.
authors.affiliation: Clinic and Policlinic of Neurology, University of Rostock, Rostock, Germany; Department of Neurology, Medical University of Vienna, Vienna, Austria.
authors.forename: P S
authors.initials: PS
authors.lastname: Rommer
authors.forename: A
authors.initials: A
authors.lastname: Dudesek
authors.forename: O
authors.initials: O
authors.lastname: Stüve
authors.forename: U K
authors.initials: UK
authors.lastname: Zettl
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors
keywords: alemtuzumab; daclizumab; multiple sclerosis; natalizumab; rituximab